Sun, 04 Dec 2022

NEW YORK, NY / ACCESSWIRE / September 28, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

KRBP Shareholders Click Here: https://www.zlk.com/pslra-1/kiromic-lawsuit-submission-form?prid=32195&wire=1
CODX Shareholders Click Here: https://www.zlk.com/pslra-1/co-dx-lawsuit-loss-submission-form?prid=32195&wire=1
SFIX Shareholders Click Here: https://www.zlk.com/pslra-1/stitch-fix-class-action-loss-submission-form?prid=32195&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Wednesday, September 28, 2022, Press release picture

Kiromic BioPharma, Inc. (NASDAQ:KRBP)

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.
Lead Plaintiff Deadline : October 4, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/kiromic-lawsuit-submission-form?prid=32195&wire=1

The complaint alleges that the registration statement and prospectus issued in connection with the Company's public offering that closed on July 2, 2021 (the 'Offering Documents') failed to disclose that the Food and Drug Administration ('FDA') had, prior to the filing of these documents, imposed a clinical hold on the Company's Investigational New Drug ('IND') applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

Co-Diagnostics, Inc. (NASDAQ:CODX)

This lawsuit is on behalf of a class of all persons and entities who purchased the publicly traded securities of Co-Dx during the period of May 12, 2022 through the close of the market on August 11, 2022 (4:00 p.m. ET).
Lead Plaintiff Deadline : October 17, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/co-dx-lawsuit-loss-submission-form?prid=32195&wire=1

According to the filed complaint, (i) demand for the Company's Logix Smart™ COVID-19 test had plummeted throughout the quarter ended June 30, 2022, and (ii) as a result, defendants' positive statements about the demand for its Logix Smart™ COVID-19 test lacked a reasonable basis.

Stitch Fix, Inc. (NASDAQ:SFIX)

This lawsuit is on behalf of purchasers of Stitch Fix Class A common stock between December 8, 2020, and March 8, 2022, inclusive.
Lead Plaintiff Deadline : October 25, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/stitch-fix-class-action-loss-submission-form?prid=32195&wire=1

According to the filed complaint, Stitch Fix made numerous false and misleading statements to investors concerning the synergy between the Company's Fix and Freestyle programs, and repeatedly denied claims that the Freestyle program could cannibalize the Company's legacy Fix business. Specifically, Stitch Fix repeatedly assured investors that the Company's Freestyle business was 'an additive experience' and 'complementary' to the Fix business, that 'the combination of those two things will allow us to address many more types of clients,' and that 'we see solid growth in both sides of the business.' In truth, Stitch Fix concealed that these programs were not complementary or additive. Stitch Fix knew that the Freestyle program would be much preferred to the Company's original Fix model and that the Freestyle program would inevitably cannibalize the Company's legacy Fix business.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/718036/CLASS-ACTION-UPDATE-for-KRBP-CODX-and-SFIX-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Sign up for Buffalo News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!